Last reviewed 2026-04-23 · How we verify

Actitan F

Federico II University · FDA-approved active Small molecule

Actitan F is a melatonin receptor agonist Small molecule drug developed by Federico II University. It is currently FDA-approved for Insomnia.

Actitan F is a melatonin receptor agonist.

Actitan F is a melatonin receptor agonist. Used for Insomnia.

At a glance

Generic name	Actitan F
Sponsor	Federico II University
Drug class	melatonin receptor agonist
Target	MT1/MT2
Modality	Small molecule
Therapeutic area	Sleep disorder
Phase	FDA-approved

Mechanism of action

Actitan F works by activating melatonin receptors, which helps regulate sleep-wake cycles. This can be beneficial for individuals with insomnia or other sleep disorders. By modulating the body's natural sleep-wake cycle, Actitan F can improve sleep quality and duration.

Approved indications

Insomnia

Common side effects

Headache
Dizziness
Nausea

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Actitan F CI brief — competitive landscape report
Actitan F updates RSS · CI watch RSS
Federico II University portfolio CI

Frequently asked questions about Actitan F

What is Actitan F?

Actitan F is a melatonin receptor agonist drug developed by Federico II University, indicated for Insomnia.

How does Actitan F work?

Actitan F is a melatonin receptor agonist.

What is Actitan F used for?

Actitan F is indicated for Insomnia.

Who makes Actitan F?

Actitan F is developed and marketed by Federico II University (see full Federico II University pipeline at /company/federico-ii-university).

What drug class is Actitan F in?

Actitan F belongs to the melatonin receptor agonist class. See all melatonin receptor agonist drugs at /class/melatonin-receptor-agonist.

What development phase is Actitan F in?

Actitan F is FDA-approved (marketed).

What are the side effects of Actitan F?

Common side effects of Actitan F include Headache, Dizziness, Nausea.

What does Actitan F target?

Actitan F targets MT1/MT2 and is a melatonin receptor agonist.

Drug class: All melatonin receptor agonist drugs
Target: All drugs targeting MT1/MT2
Manufacturer: Federico II University — full pipeline
Therapeutic area: All drugs in Sleep disorder
Indication: Drugs for Insomnia

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing